Company facts
- Headquarters
- Woodland Hills, California
- Most recent report
- 8-K, filed Jan 3, 2024
- Incorporated
- Delaware
- Filings on record
- 502 filings
- On EDGAR
- CIK 1528172
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 58
News 8 of 32
Prospectuses and Registrations 8 of 17
- 424B3 Prospectus supplement for an offering Jul 16, 2020
- S-1/A Registration statement for an offering, amended Jul 10, 2020
- S-1 Registration statement for an offering Jun 23, 2020
- POS AM Post-effective amendment to a registration Jun 2, 2020
- S-1/A Registration statement for an offering, amended Jan 8, 2019
- S-1 Registration statement for an offering Jan 7, 2019
- 424B3 Prospectus supplement for an offering Oct 19, 2016
- S-1/A Registration statement for an offering, amended Oct 17, 2016
Proxies 1
Ownership 8 of 308
- 4 Insider reported a trade Jul 7, 2020
- 4 Insider reported a trade Feb 26, 2020
- 4/A Insider reported a trade, amended Jan 24, 2020
- 4/A Insider reported a trade, amended Jan 24, 2020
- 4 Insider reported a trade Jan 23, 2020
- 4 Insider reported a trade Dec 31, 2019
- 4 Insider reported a trade Dec 9, 2019
- 4 Insider reported a trade Nov 26, 2019
Other 8 of 86
- SEC STAFF ACTION Sep 19, 2024
- 15-12G Feb 2, 2024
- NT 10-Q Notice that a quarterly report will be late Nov 15, 2023
- 1-A/A Amended filing Aug 25, 2023
- NT 10-Q Notice that a quarterly report will be late Aug 15, 2023
- 1-A/A Amended filing Jun 14, 2023
- NT 10-Q Notice that a quarterly report will be late May 16, 2023
- NT 10-K Notice that an annual report will be late Mar 31, 2023
Everything here comes from Endonovo Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.